Pneumococcal penicillin resistance and the cost-effectiveness of pneumococcal vaccine

Infections in Medicine

Volumn 15, Issue 4, 1998, Pages

  Herman, Christopher M ^a   Chen, G John ^a   High, Kevin P ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Cost effectiveness; Penicillin resistance; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; BACTEREMIA; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PENICILLIN RESISTANCE; PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINE PRODUCTION;

EID: 0031960928     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Reichler MR, Allphin AA, Breiman RF, et al: The spread of multiple-resistant Streptococcus pneumoniae at a day care center in Ohio. J Infect Dis 166:1346-1353, 1992.
2. Austrian R, Gold J: Pneumococcal bacteremia with special reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60:759, 1964.
3. Thornsberry C, Brown SD, Yee YC, et al: Increasing penicillin resistance in Streptococcus pneumoniae in the US: Effect on susceptibility to oral cephalosporins. Infect Med 4:15-24, 1993.
4. Barry AL, Pfaller MA, Fuchs PC, et al: In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 38:2419-2425, 1994.
5. Centers for Disease Control and Prevention: Prevalence of penicillin-resistant Streptococcus pneumoniae in Connecticut, 1992-1993. MMWR 43:216-217,223, 1994.
6. Centers for Disease Control and Prevention: Drug-resistant Streptococcus pneumoniae in Kentucky and Tennessee, 1993. MMWR 43:23-25,31, 1994.
7. Hofmann J, Cetron MS, Farley MM, et al: The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 333:481-486, 1995.
8. Fedson DS: Influenza and pneumococcal vaccination of the elderly: Newer vaccines and prospects for clinical benefits at the margin. Prev Med 23:751-755, 1994.
9. Breiman RF, Spika JS, Navarro VJ, et al: Pneumococcal bacteremia in Charleston County, South Carolina: A decade later. Arch Intern Med 150(7):1401-1405, 1990.
10. Spika JS, Fedson DS, Facklam R: Pneumococcal vaccination: Controversies and opportunities. Infect Dis Clin North Am 4:11-27, 1990.
11. Plouffe JF, Breiman RF, Facklam RR: Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention. JAMA 275(3):194-198, 1996.
12. Sloas MM, Barrett FF, Chesney PJ, et al: Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis. Pediatr Infect Dis J 11:662-666, 1992.
13. Chandy CJ: Treatment failure with the use of a third-generation cephalosporin for penicillin-resistant pneumococcal meningitis: Case report and review. Clin Infect Dis 18:188-193, 1994.
14. Bradley JS, Connor JD: Ceftriaxone failure in meningitis caused by Streptococcus pneumoniae with reduced susceptibility to beta-lactam antibiotics. Pediatr Infect Dis 10:871-873, 1991.
15. Pallares R, Linares J, Vadillo M, et al: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 333:474-480, 1995.
16. Lonks JR, Medeiros AA: The growing threat of antibiotic-resistant Streptococcus pneumoniae. Med Clin North Am 79(3):523-535, 1995.
17. Fedson DS: Clinical practice and public policy for influenza and pneumococcal vaccination of the elderly. Clin Geriatr Med 8(1):183-199, 1992.
18. Robbins JB, Austrian R, Lee CJ, et al: Considerations for formulating the second generation pneumococcal polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 148:1136-1159, 1983.
19. Jorgenson JH, Howell AW, Maher LA, et al: Serotypes of respiratory isolates of Streptococcus pneumoniae compared with the capsular types included in the current pneumococcal vaccine. J Infect Dis 163:664-666, 1991.
20. Butler JC, Breiman RF, Campbell JF, et al: Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations. JAMA 270:1826-1831, 1993.
21. Shapiro ED, Berg AT, Austrian R, et al: The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325:1453-1460, 1991.
22. Ammann AJ, Schiffman G, Austrian R, et al: The antibody response to pneumococcal capsular polysaccharides in aged individuals. Proc Soc Exp Biol Med 164(3):312-316, 1980.
23. Centers for Disease Control and Prevention: Pneumococcal polysaccharide vaccine. MMWR 38:64-67,68-77, 1989.
24. Centers for Disease Control and Prevention: Influenza and pneumococcal vaccination coverage levels among persons aged 65 years in the US, 1973-1993. MMWR 44(27):507-515, 1995.
25. Willems JS, Sanders CR, Riddiough MA, et al: Cost effectiveness of vaccination against pneumococcal pneumonia. N Engl J Med 303(10):553-559, 1980.
26. Office of Technology Assessment: US Congress: A review of selected Federal vaccine and immunization policies. Washington, D.C., 1979.
27. Sisk JE, Riegelman RK: Cost effectiveness of vaccination against pneumococcal pneumonia: An update. Ann Intern Med 104:79-86, 1986.
28. Fedson DS: Pneumococcal vaccination in the prevention of community-acquired pneumonia: An optimistic view of cost-effectiveness. Semin Respir Infect 8(4):285-293, 1993.
29. Gable CB, Holzer SS, Engelhart L, et al: Pneumococcal vaccine efficacy and associated cost savings. JAMA 264(22):2910-2915, 1990.
30. Agency for Health Care Policy and Research: Healthcare Cost and Utilization Project-3. February 1996, Pub. No. 96-0028.
31. Wylie CM: Contrasts in the health of elderly men and women: An analysis of recent data for whites in the United States. J Am Geriatr Soc 32(9):670-675, 1984.
32. Fedson DS, Waida A, Nicol JP, et al: "The old man's friend." Lancet 342:561, 1993. Letter.